top of page
人脂質運載蛋白-2 ELISA 試劑盒

人脂質運載蛋白-2 ELISA 試劑盒

庫存單位: 31050

  下載數據表 PDF 

★ 下載 MSDS ★

 

化驗 範圍:  0.39  – 25 納克/毫升

套件尺寸:  96 孔/試劑盒

其他名稱:  LCN2、NGAL、中性粒細胞脂質運載蛋白 (NL)、24p3、鐵運載蛋白、MSFI

  • 介紹

    Lipocalin-2,也稱為中性粒細胞明膠酶相關脂質運載蛋白 (NGAL)、24p3、siderocalin 或中性粒細胞脂質運載蛋白 (NL),是一種在肝、肺、腎、脂肪細胞、活化的中性粒細胞和巨噬細胞中表達的分泌糖蛋白。
    Lipocalin-2 在各種炎症和感染條件下上調,可作為各種腎損傷的敏感生物標誌物。血清 lipocalin-2 水平與人類肥胖、胰島素抵抗、高血糖、冠心病和脂肪肝呈正相關。

  • 測定原理

    該測定是使用針對人 LCN2 的單克隆抗體的定量夾心 ELISA。免疫板預先塗有對人 LCN2 特異的單克隆抗體。將標準品和样品加入孔中,任何存在的人 LCN2 都會被固定化抗體捕獲。洗去任何未結合的物質後,將辣根過氧化物酶 (HRP) 連接的特異於人 LCN2 的單克隆抗體添加到孔中。在最後的洗滌步驟去除任何未結合的試劑後,加入 HRP 底物溶液,顏色與最初結合的人 LCN2 的量成比例。停止反應並使用酶標儀測定孔的光密度。由於吸光度的增加與捕獲的人 LCN2 的量成正比,因此可以從每個分析中包含的參考曲線中插入未知樣品濃度。

  • 檢測性能

    一種。 標準曲線的典型代表

    以下標準曲線僅供演示。應為每組樣品測定生成標準曲線。

    人 lipocalin-2 (ng/mL)

    吸光度 (450 nm)

    消隱吸光度

    0

    0.076

    0

    0.39

    0.107

    0.031

    0.78

    0.137

    0.061

    1.56

    0.203

    0.127

    3.12

    0.343

    0.267

    6.25

    0.647

    0.571

    12.5

    1.26

    1.184

    25

    2.492

    2.416

     

    B. 敏感性

    該測定法可檢測到的 lipocalin-2 的最低水平為 0.39 納克/毫升。

     

    C. 特異性

    該檢測中使用的抗體對對人 lipocalin-2 具有特異性,不會與小鼠和大鼠 lipocalin-2 以及其他細胞因子或激素分子發生交叉反應。

  • PUBLICATIONS CITING THIS PRODUCT

    1. Alkharfy KM, Al-Daghri NM, Vanhoutte PM, Krishnaswamy S, Xu A. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PloS one. 2012 Oct 31;7(10):e48612.
    2. Xiao Y, Xu A, Hui X, Zhou P, Li X, Zhong H, Tang W, Huang G, Zhou Z. Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes. PLoS One. 2013 Jun 17;8(6):e66607.
    3. Heilbronn LK, Campbell LV, Xu A, Samocha-Bonet D. Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PloS one. 2013 Oct 18;8(10):e78864.
    4. Ni J, Ma X, Zhou M, Pan X, Tang J, Hao Y, Lu Z, Gao M, Bao Y, Jia W. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovascular diabetology. 2013 Dec;12(1):1-7.
    5. Wu G, Li H, Fang Q, Jiang S, Zhang L, Zhang J, Hou X, Lu J, Bao Y, Xu A, Jia W. Elevated circulating lipocalin-2 levels independently predict incident cardiovascular events in men in a population-based cohort. Arteriosclerosis, thrombosis, and vascular biology. 2014 Nov;34(11):2457-64.
    6. Chen DL, Liess C, Poljak A, Xu A, Zhang J, Thoma C, Trenell M, Milner B, Jenkins AB, Chisholm DJ, Samocha-Bonet D. Phenotypic characterization of insulin-resistant and insulin-sensitive obesity. The Journal of Clinical Endocrinology & Metabolism. 2015 Nov 1;100(11):4082-91.
    7. Na GY, Yoon SR, An J, Yeo R, Song J, Jo MN, Han S, Kim OY. The relationship between circulating neutrophil gelatinase-associated lipocalin and early alteration of metabolic parameters is associated with dietary saturated fat intake in non-diabetic Korean women. Endocrine journal. 2016:EJ16-0233.
    8. Luo Y, Ma X, Pan X, Xu Y, Xiong Q, Xiao Y, Bao Y, Jia W. Serum lipocalin-2 levels are positively associated with not only total body fat but also visceral fat area in Chinese men. Medicine. 2016 Jul;95(30).
    9. Chen DL, Brown R, Liess C, Poljak A, Xu A, Zhang J, Trenell M, Jenkins A, Chisholm D, Samocha-Bonet D, Macefield VG. Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men. Frontiers in physiology. 2017 Feb 28;8:101.
    10. Yang K, Deng HB, Man AW, Song E, Zhang J, Luo C, Cheung BM, Yuen KY, Jensen PS, Irmukhamedov A, Elie AG. Measuring non‐polyaminated lipocalin‐2 for cardiometabolic risk assessment. ESC heart failure. 2017 Nov;4(4):563-75.
    11. Sun WY, Bai B, Luo C, Yang K, Li D, Wu D, Félétou M, Villeneuve N, Zhou Y, Yang J, Xu A. Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury. JCI insight. 2018 Sep 6;3(17).
    12. Wong YK, Cheung CY, Tang CS, Au KW, Hai JS, Lee CH, Lau KK, Cheung BM, Sham PC, Xu A, Lam KS. Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology. 2018 Oct;38(10):2519-27.
    13. Elie AG, Bloksgaard M, Sun WY, Yang K, Man AW, Xu A, Irmukhamedov A, Riber LP, Wang Y, De Mey JG. Local enrichment of fatty acid-binding protein 4 in the pericardial cavity of cardiovascular disease patients. PloS one. 2018 Nov 5;13(11):e0206802.
    14. Xu Y, Ma X, Pan X, He X, Xiao Y, Bao Y. Correlations between serum concentration of three bone-derived factors and obesity and visceral fat accumulation in a cohort of middle aged men and women. Cardiovascular diabetology. 2018 Dec;17(1):1-9.
    15. Xiao Y, Xiao X, Xu A, Chen X, Tang W, Zhou Z. Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes. Journal of Diabetes and its Complications. 2018 Dec 1;32(12):1100-4.
    16. Tang A, Coster AC, Tonks KT, Heilbronn LK, Pocock N, Purtell L, Govendir M, Blythe J, Zhang J, Xu A, Chisholm DJ. Longitudinal changes in insulin resistance in normal weight, overweight and obese individuals. Journal of clinical medicine. 2019 May;8(5):623.
    17. Wu L, Qian L, Zhang L, Zhang J, Zhou J, Li Y, Hou X, Fang Q, Li H, Jia W. Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. Journal of the American Heart Association. 2020 Jun 2;9(11):e015226.
    18. Harari A, Coster AC, Jenkins A, Xu A, Greenfield JR, Harats D, Shaish A, Samocha-Bonet D. Obesity and insulin resistance are inversely associated with serum and adipose tissue carotenoid concentrations in adults. The Journal of nutrition. 2020 Jan 1;150(1):38-46.
    19. Ong KL, Wu L, Januszewski AS, O'Connell RL, Xu A, Rye KA, Ma RC, Li H, Jenkins AJ, Jia W, Keech AC. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Research and Clinical Practice. 2020 Nov 1;169:108450.
    20. Botta A, Forest A, Daneault C, Pantopoulos K, Tantiworawit A, Phrommintikul A, Chattipakorn S, Chattipakorn N, Des Rosiers C, Sweeney G. Identification of Circulating Endocan-1 and Ether Phospholipids as Biomarkers for Complications in Thalassemia Patients. Metabolites. 2021 Feb;11(2):70.
    21. Cheng F, Ng NY, Tam CH, Zhang Y, Lim CK, Jiang G, Ng AC, Yau TT, Cheung LP, Xu A, Chan JC. Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS. Endocrine connections. 2021 Oct 1;10(10):1243-52.
    22. Gan J, Zheng Y, Yu Q, Zhang Y, Xie W, Shi Y, Yu N, Yan Y, Lin Z, Yang H. Serum Lipocalin-2 Levels Are Increased and Independently Associated With Early-Stage Renal Damage and Carotid Atherosclerotic Plaque in Patients With T2DM. Front Endocrinol (Lausanne). 2022 Apr 25;13:855616.
$407.00價格

如需批量訂單(數量:5 個或更多),請聯繫我們獲取報價

bottom of page